Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Alzheimer's drugs
Pharma
Padcev-Keytruda result, Alzheimer's med, Fosun—Fierce Pharma Asia
The Padcev-Keytruda combo notched another phase 3 win. China didn't renew an Alzheimer's drug's conditional nod. Fosun out-licensed a DPP1 inhibitor.
Angus Liu
Aug 15, 2025 8:31am
China did not renew approval of controversial Alzheimer's drug
Aug 14, 2025 11:22am
FDA clears Lilly’s new Kisunla regimen with fewer side effects
Jul 9, 2025 6:45am
EMA changes tune, endorses Leqembi with restriction
Nov 14, 2024 12:10pm
Suboptimal Leqembi vials could create millions in waste: study
Oct 14, 2024 3:00pm
Eisai, Biogen's Leqembi nabs UK nod but not reimbursement
Aug 22, 2024 9:23am
